MaxCyte agrees to $151.8M Akron deal, lifts 2026 outlook

By Grace Kim

MaxCyte’s $151.8 million agreement to acquire Akron Bio would nearly double the cell-engineering company’s revenue base, with Akron expected to generate $28 million of revenue in 2026. Executives said on the third-quarter earnings call that the pending transaction would also accelerate MaxCyte’s path to profitability.

What does the Akron acquisition change?

MaxCyte agreed to buy Akron from Arcline Investment Management for $105 million in cash, approximately $26.8 million in MaxCyte common stock and $20 million in guaranteed deferred payments. The deferred amount is payable in $10 million installments in 2028 and 2029.

For 2026, management expects Akron to generate $28 million in revenue and $7 million to $8 million in EBITDA (earnings before interest, taxes, depreciation and amortization).

Akron supplies cytokines, growth factors, cell culture media and cryopreservation products used in cell therapy manufacturing. CEO Maher Masoud said: “Akron’s products support manufacturing steps around MaxCyte’s cell-engineering technology.” Masoud also said the products are used in both viral and non-viral therapies.

Masoud said four commercially approved therapies specify Akron’s products, with four additional programs following registrational pathways, or paths toward regulatory approval. The combined company would support five approved therapies and be embedded in more than 95 clinical-stage programs, including more than 85 from Akron.

• Commercial mix: About 30% of combined revenue is expected from commercial-stage customers.
• Customer concentration: The largest customer would account for about 14% of revenue, compared with 27% for MaxCyte standalone.
• Cross-selling: Current customer overlap is about 10%, creating a cross-sell opportunity.

CFO Parmeet Ahuja said Akron generated approximately $23 million in revenue in 2025 and delivered low- to mid-teens annualized revenue growth since 2018. MaxCyte expects that growth trend to continue in 2027 and estimates approximately $3 million to $4 million in potential cost efficiencies from integrating the businesses.

Takeaway: The deal adds scale and cross-selling potential, but the transaction remains unfinished.

How did third-quarter performance change?

Total revenue rose 49% to $10.2 million for the quarter ended Sept. 30, 2026, from $6.8 million a year earlier. Core revenue increased 27% to $8.2 million, led by instrument sales, which doubled to $2.8 million from $1.4 million.

Some instrument purchases by a partner occurred in the third quarter rather than the fourth. Masoud said demand across the broader customer base grew at a double-digit rate even excluding that customer.

Processing assembly revenue rose to $3.1 million from $2.6 million, while license revenue increased to $2 million from $1.8 million. Ahuja said earlier inventory drawdowns and partner-program challenges were behind MaxCyte, and he expected processing assembly revenue to grow from a stable base.

Strategic platform license, or SPL, program-related revenue rose to $2 million from $400,000. The quarter included a $1 million milestone tied to dosing in a partner’s pivotal, or late-stage, trial and approximately $1 million in royalties. Ahuja attributed part of the year-over-year increase to higher royalty revenue from continued Casgevy adoption.

Gross margin increased to 83% from 77%, while operating expenses fell 25% to $14.5 million, reflecting restructuring and efficiency measures taken in 2025. MaxCyte’s year-to-date net loss narrowed to approximately $18 million from about $35 million in the comparable 2025 period.

Takeaway: Stronger sales and lower costs narrowed the loss.

What does the outlook mean for liquidity?

MaxCyte now expects at least $34.5 million in standalone revenue, meaning revenue without Akron, for 2026, up from approximately $34 million in its October outlook. The forecast comprises approximately $28 million in core revenue and at least $6.5 million in SPL milestones and royalties, and it excludes any Akron contribution.

MaxCyte ended the quarter with $132.7 million in cash, equivalents and investments and no debt. It entered a credit facility of up to $75 million with MidCap Financial to help fund the acquisition and preserve liquidity. At closing, MaxCyte expects to draw $20 million under a term loan and $2 million under a revolving facility, or reusable credit line.

Ahuja expects MaxCyte to hold $40 million to $45 million in cash when the acquisition closes. The combined company’s annual cash burn, or cash use, is expected to stay below $10 million in 2027, including reduced interest income and interest expense associated with the debt facility.

MaxCyte also projected at least $133 million in year-end cash, equivalents and investments on a pro forma, or adjusted, basis. The calculation excludes acquisition consideration and related costs, as well as any further capital deployed toward share repurchases.

Ahuja said the figure is intended for comparison with the September balance and “should not be viewed as a forecast of actual year-end cash.”

Takeaway: MaxCyte raised its standalone forecast slightly and arranged financing while expecting $40 million to $45 million in cash at closing.

What does MaxCyte sell?

MaxCyte, listed on Nasdaq as MXCT, develops technologies for engineering cells used in biopharmaceutical research and the development of cell-based therapies. Its platform helps researchers modify cells efficiently for cell therapy, gene editing, immuno-oncology and other advanced biological treatments.

The company’s primary offering, the ExPERT platform, combines Flow Electroporation technology with specialized instruments, single-use processing assemblies, software and related support services.

Takeaway: MaxCyte’s core offering combines cell-engineering technology with instruments, assemblies, software and support.